KLAR — Klaria Pharma Holding AB (publ) Income Statement
0.000.00%
- SEK46.86m
- SEK45.93m
Annual income statement for Klaria Pharma Holding AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.22 | 0 | 0 | 5.87 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 25.3 | 48.7 | 50.1 | 60.8 | 14.7 |
Operating Profit | -21.1 | -48.7 | -50.1 | -55 | -14.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.5 | -51.4 | -53.5 | -63.7 | -18.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22.5 | -51.4 | -53.5 | -63.8 | -18.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -22.5 | -51.4 | -53.5 | -63.8 | -35.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -22.5 | -51.4 | -53.5 | -63.8 | -35.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.677 | -1.11 | -0.969 | -1.03 | -0.182 |
Dividends per Share |